# Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

> **NCT02976896** · PHASE2 · COMPLETED · sponsor: **Yuhong Li** · enrollment: 43 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT02976896
- **Lead sponsor:** Yuhong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-12
- **Final completion:** 2022-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976896, "Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02976896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*